Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Connect Biopharma Holdings (CNTB) Change in Accured Expenses (2024 - 2025)

Connect Biopharma Holdings (CNTB) has disclosed Change in Accured Expenses for 2 consecutive years, with $2.2 million as the latest value for Q4 2025.

  • Quarterly Change in Accured Expenses rose 319.29% to $2.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.4 million through Dec 2025, up 300.24% year-over-year, with the annual reading at $3.4 million for FY2025, 300.24% up from the prior year.
  • Change in Accured Expenses hit $2.2 million in Q4 2025 for Connect Biopharma Holdings, up from $999000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $2.2 million in Q4 2025 to a low of -$1.3 million in Q2 2024.